Direct Real‐Time Monitoring of Prodrug Activation by Chemiluminescence. Issue 29 (19th June 2018)

• Record Type: Journal Article
• Authors: Gnaim, Samer; Scomparin, Anna; Das, Sayantan; Blau, Rachel; Satchi‐Fainaro, Ronit; Shabat, Doron
• Is Part Of: Angewandte Chemie international edition. Volume 57:Issue 29(2018)
• Page Start: 9033
• Page End: 9037
• Publication Date: 2018-06-19
• Subjects: chemiluminescence -- fluorescence probes -- molecular imaging -- prodrugs -- theranostics; Chemistry -- Periodicals; 540
• DOI: 10.1002/anie.201804816
• Languages: English
• ISSNs: 1433-7851

Abstract

Abstract: The majority of theranostic prodrugs reported so far relay information through a fluorogenic response generated upon release of the active chemotherapeutic agent. A chemiluminescence detection mode offers significant advantages over fluorescence, mainly due to the superior signal‐to‐noise ratio of chemiluminescence. Here we report the design and synthesis of the first theranostic prodrug monitored by a chemiluminescence diagnostic mode. As a representative model, we prepared a prodrug from the chemotherapeutic monomethyl auristatin E, which was modified for activation by β‐galactosidase. The activation of the prodrug in the presence of β‐galactosidase is accompanied by emission of a green photon. Light emission intensities, which increase with increasing concentration of the prodrug, were linearly correlated with a decrease in the viability of a human cell line that stably expresses β‐galactosidase. We obtained sharp intravital chemiluminescent images of endogenous enzymatic activity in β‐galactosidase‐overexpressing tumor‐bearing mice. The exceptional sensitivity achieved with the chemiluminescence diagnostic mode should allow the exploitation of theranostic prodrugs for personalized cancer treatment. Abstract : Ray of light : A chemiluminescence detection mode offers significant advantages over fluorescence, mainly due to a superior signal‐to‐noise ratio. A theranostic prodrug that is monitored through a chemiluminescence diagnostic mode was designed. As a representative example, a prodrug was prepared from the chemotherapeutic monomethyl auristatin E, which was modified for activation by β‐galactosidase.